Literature DB >> 22809589

Xerostomia: a day and night difference.

Tim Dijkema1, Cornelis P J Raaijmakers, Pètra M Braam, Judith M Roesink, Evelyn M Monninkhof, Chris H J Terhaard.   

Abstract

PURPOSE: To compare patient-reported xerostomia during daytime and during nighttime with objectively measured parotid and submandibular gland function in a cohort of head-and-neck cancer (HNC) patients treated with RT.
MATERIALS AND METHODS: A cohort of 138 HNC patients underwent objective measurements of parotid (PF) and submandibular (SMF) gland function and completed a xerostomia questionnaire (XQ) before RT, at 6 weeks, 6 months and 1 year after RT. No attempt was made to spare the submandibular gland(s). The XQ contained specific questions concerning the sensation of dry mouth during day- (XD) and nighttime (XN), scored on a 5-point Likert scale. Patients with no or mild (grade 1-3) xerostomia and patients with more severe (grade 4-5) complaints were grouped together.
RESULTS: Before RT, no association existed between dry mouth complaints and PF or SMF. At 6 weeks, 6 months and 1 year after RT; 37%, 51% and 36% had grade 4-5 XD and 65%, 64% and 56% had grade 4-5 XN, respectively. Patients with grade 4-5 XD and XN had significantly worse SMF at all time points after RT compared to patients with grade 1-3 XD and XN, while PF was significantly worse only at 6 weeks after RT. In multivariate analyses, SMF was consistently the most important factor related to XN after treatment. PF significantly influenced XD at 6 weeks and 1 year after RT.
CONCLUSIONS: Differentiating between complaints during day- and nighttime in xerostomia research is necessary. Dry mouth at night is a frequent problem after (parotid-sparing) RT for HNC and is explained by submandibular gland dysfunction. Sparing of the contralateral submandibular gland, in addition to parotid gland sparing, may result in improved patient-reported xerostomia.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22809589     DOI: 10.1016/j.radonc.2012.06.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Tyrosine Kinase Inhibitors Protect the Salivary Gland from Radiation Damage by Inhibiting Activation of Protein Kinase C-δ.

Authors:  Sten M Wie; Elizabeth Wellberg; Sana D Karam; Mary E Reyland
Journal:  Mol Cancer Ther       Date:  2017-06-21       Impact factor: 6.261

2.  Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?

Authors:  Daan Nevens; Sandra Nuyts
Journal:  Br J Radiol       Date:  2017-10-03       Impact factor: 3.039

3.  Prognostic Factors for Complete Recovery From Xerostomia After Radiotherapy of Head-and-Neck Cancers.

Authors:  Dirk Rades; Britta Warwas; Karsten Gerull; Ralph Pries; Anke Leichtle; Karl L Bruchhage; Samer G Hakim; Steven E Schild; Florian Cremers
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

4.  Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia.

Authors:  Jianzhong Cao; Xiaodong Zhang; Bo Jiang; Jiayun Chen; Xiaochun Wang; Li Wang; Narayan Sahoo; X Ronald Zhu; Rong Ye; Pierre Blanchard; Adam S Garden; C David Fuller; G Brandon Gunn; Steven J Frank
Journal:  Radiother Oncol       Date:  2021-04-08       Impact factor: 6.901

5.  GTV delineation in supraglottic laryngeal carcinoma: interobserver agreement of CT versus CT-MR delineation.

Authors:  Elise Anne Jager; Nicolien Kasperts; Joana Caldas-Magalhaes; Mariëlle E P Philippens; Frank A Pameijer; Chris H J Terhaard; Cornelis P J Raaijmakers
Journal:  Radiat Oncol       Date:  2015-01-23       Impact factor: 3.481

6.  Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma.

Authors:  Sven van den Bosch; Tim Dijkema; Martina C Kunze-Busch; Chris H J Terhaard; Cornelis P J Raaijmakers; Patricia A H Doornaert; Frank J P Hoebers; Marije R Vergeer; Bas Kreike; Oda B Wijers; Wim J G Oyen; Johannes H A M Kaanders
Journal:  BMC Cancer       Date:  2017-03-21       Impact factor: 4.430

Review 7.  Regional Responses in Radiation-Induced Normal Tissue Damage.

Authors:  Daniëlle C Voshart; Julia Wiedemann; Peter van Luijk; Lara Barazzuol
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

8.  Sialendoscopy for Improvement of Salivary Flow in Patients with Sjögren Syndrome - Comparative Analysis of Intraglandular Washing Solutions.

Authors:  Gabriela Robaskewicz Pascoto; Andrese Aline Gasparin; Otávio Bejzman Piltcher; Gabriel Kuhl; Leandro Totti Cavazzola
Journal:  Int Arch Otorhinolaryngol       Date:  2020-09-30

9.  Proton Radiation Therapy for Nasopharyngeal Cancer Patients: Dosimetric and NTCP Evaluation Supporting Clinical Decision.

Authors:  Alessandro Vai; Silvia Molinelli; Eleonora Rossi; Nicola Alessandro Iacovelli; Giuseppe Magro; Anna Cavallo; Emanuele Pignoli; Tiziana Rancati; Alfredo Mirandola; Stefania Russo; Rossana Ingargiola; Barbara Vischioni; Maria Bonora; Sara Ronchi; Mario Ciocca; Ester Orlandi
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 10.  The role of stem cells in the prevention and treatment of radiation-induced xerostomia in patients with head and neck cancer.

Authors:  Daan Nevens; Sandra Nuyts
Journal:  Cancer Med       Date:  2016-02-16       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.